Yazar "Mogulkoc, N." seçeneğine göre listele
Listeleniyor 1 - 19 / 19
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Airway inter-tapering and tortuosity predict mortality in idiopathic pulmonary fibrosis(European Respiratory Soc Journals Ltd, 2022) Cheung, W. K.; Pakzad, A.; Mogulkoc, N.; Savas, R.; Alexander, D. C.; Hu, Y.; Hurst, J. R.[No abstract available]Öğe Automated airway quantification associates with mortality in idiopathic pulmonary fibrosis(Springer Science and Business Media Deutschland GmbH, 2023) Cheung, W.K.; Pakzad, A.; Mogulkoc, N.; Needleman, S.; Rangelov, B.; Gudmundsson, E.; Zhao, A.Objectives: The study examined whether quantified airway metrics associate with mortality in idiopathic pulmonary fibrosis (IPF). Methods: In an observational cohort study (n = 90) of IPF patients from Ege University Hospital, an airway analysis tool AirQuant calculated median airway intersegmental tapering and segmental tortuosity across the 2nd to 6th airway generations. Intersegmental tapering measures the difference in median diameter between adjacent airway segments. Tortuosity evaluates the ratio of measured segmental length against direct end-to-end segmental length. Univariable linear regression analyses examined relationships between AirQuant variables, clinical variables, and lung function tests. Univariable and multivariable Cox proportional hazards models estimated mortality risk with the latter adjusted for patient age, gender, smoking status, antifibrotic use, CT usual interstitial pneumonia (UIP) pattern, and either forced vital capacity (FVC) or diffusion capacity of carbon monoxide (DLco) if obtained within 3 months of the CT. Results: No significant collinearity existed between AirQuant variables and clinical or functional variables. On univariable Cox analyses, male gender, smoking history, no antifibrotic use, reduced DLco, reduced intersegmental tapering, and increased segmental tortuosity associated with increased risk of death. On multivariable Cox analyses (adjusted using FVC), intersegmental tapering (hazard ratio (HR) = 0.75, 95% CI = 0.66–0.85, p < 0.001) and segmental tortuosity (HR = 1.74, 95% CI = 1.22–2.47, p = 0.002) independently associated with mortality. Results were maintained with adjustment using DLco. Conclusions: AirQuant generated measures of intersegmental tapering and segmental tortuosity independently associate with mortality in IPF patients. Abnormalities in proximal airway generations, which are not typically considered to be abnormal in IPF, have prognostic value. Clinical relevance statement: Quantitative measurements of intersegmental tapering and segmental tortuosity, in proximal (second to sixth) generation airway segments, independently associate with mortality in IPF. Automated airway analysis can estimate disease severity, which in IPF is not restricted to the distal airway tree. Key Points: • AirQuant generates measures of intersegmental tapering and segmental tortuosity. • Automated airway quantification associates with mortality in IPF independent of established measures of disease severity. • Automated airway analysis could be used to refine patient selection for therapeutic trials in IPF. Graphical Abstract: [Figure not available: see fulltext.] © 2023, The Author(s).Öğe Clinical and prognostic significance of heart rate variability in pulmonary arterial hypertension(Oxford Univ Press, 2014) Kayikcioglu, M.; Musayev, O.; Nalbantgil, S.; Mogulkoc, N.; Vuran, O.; Musayev, K.; Kultursay, H.Öğe Clinical and Prognostic Significance of Heart Rate Variability in Pulmonary Hypertension(Elsevier Science Inc, 2014) Musayev, O.; Kayikcioglu, M.; Nalbantgil, S.; Mogulkoc, N.; Vuran, O.; Musayev, K.; Kultursay, H.Öğe Clinical Characteristics and Survival According to the Presence of Velcro Crackles in the European Multipartner IPF Registry (EMPIRE)(Amer Thoracic Soc, 2023) Lang, D.; Lamprecht, B.; Mogulkoc, N.; Sterclova, M.; Lewandowska, K.; Kramer, M.; Bartos, V.[No abstract available]Öğe COST-EFFECTIVENESS OF RIOCIGUAT FOR TREATMENT OF PATIENTS WITH INOPERABLE OR POST-OPERATIVE RECURRENT/PERSISTENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN TURKEY(Elsevier Science Inc, 2015) Erdal, E.; Ozdemir, O.; Yildizeli, B.; Kaymaz, C.; Okumus, G.; Mogulkoc, N.; Nalbantgil, S.; Deger, C.; Sumer, F.; Parali, E.; Tunalioglu, A.; Sar, C.; Asan, S.; Ozel, O.Öğe COST-EFFECTIVENESS OF RIOCIGUAT FOR TREATMENT OF PATIENTS WITH INOPERABLE OR POST-OPERATIVE RECURRENT/PERSISTENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN TURKEY(Elsevier Science Inc, 2015) Erdal, E.; Ozdemir, O.; Yildizeli, B.; Kaymaz, C.; Okumus, G.; Mogulkoc, N.; Nalbantgil, S.; Deger, C.; Sumer, F.; Parali, E.; Tunalioglu, A.; Sar, C.; Asan, S.; Ozel, O.Öğe COST-EFFECTIVENESS OF RIOCIGUAT FOR TREATMENT OF PATIENTS WITH INOPERABLE OR POST-OPERATIVE RECURRENT/PERSISTENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN TURKEY(Elsevier Science Inc, 2015) Erdal, E.; Ozdemir, O.; Yildizeli, B.; Kaymaz, C.; Okumus, G.; Mogulkoc, N.; Nalbantgil, S.; Deger, C.; Sumer, F.; Parali, E.; Tunalioglu, A.; Sar, C.; Asan, S.; Ozel, O.Öğe THE DIRECT COST COMPONENTS IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS(Elsevier Science Inc, 2016) Mogulkoc, N.; Okumus, G.; Yildizeli, B.; Kaymaz, C.; Nalbantgil, S.; Ozdemir, O.; Erdal, E.; Sar, C.Öğe THE DIRECT COST-COMPONENTS IN PULMONARY ARTERIAL HYPERTENSION: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS(Elsevier Science Inc, 2016) Mogulkoc, N.; Okumus, G.; Yildizeli, B.; Kaymaz, C.; Nalbantgil, S.; Ozdemir, O.; Erdal, E.; Sar, C.Öğe Effect of Nintedanib on Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF): Results from a Phase IIIb Trial(Amer Thoracic Soc, 2018) Lancaster, L. H.; Conoscenti, C. S.; Ilowite, J.; Trampisch, M.; Mogulkoc, N.; Homik, L.; Kaye, M.Öğe Effects of Visually Scored Pleuroparenchymal Fibroelastosis Severity on Functional Decline and Mortality in IPF Patients(Amer Thoracic Soc, 2021) Gudmundsson, E.; Zhao, A.; Mogulkoc, N.; Jones, M. G.; Moorsel, C. V.; Savas, R.; Brereton, C. J.[No Abstract Available]Öğe Evaluation of automated airway morphological quantification for assessing fibrosing lung disease(Taylor & Francis Ltd, 2024) Pakzad, A.; Cheung, W. K.; Van Moorsel, C. H. M.; Quan, K.; Mogulkoc, N.; Bartholmai, B. J.; Van Es, H. W.Abnormal airway dilatation, termed traction bronchiectasis, is a typical feature of idiopathic pulmonary fibrosis (IPF). Volumetric computed tomography (CT) imaging captures the loss of normal airway tapering in IPF. We postulated that automated quantification of airway abnormalities could provide estimates of IPF disease extent and severity. We propose AirQuant, an automated computational pipeline that takes an airway segmentation and CT image as input and systematically parcellates the airway tree into its lobes and generational branches, deriving airway structural measures from chest CT. Importantly, AirQuant prevents the occurrence of spurious airway branches by thick wave propagation and removes loops in the airway-tree by graph search, overcoming limitations of existing airway skeletonisation algorithms. Tapering between airway segments (intertapering) and airway tortuosity computed by AirQuant were compared between 14 healthy participants and 14 IPF patients. Airway intertapering was significantly reduced in IPF patients, and airway tortuosity was significantly increased when compared to healthy controls. Differences were most marked in the lower lobes, conforming to the typical distribution of IPF-related damage. AirQuant is an open-source pipeline that avoids limitations of existing airway quantification algorithms and has clinical interpretability. Automated airway measurements may have potential as novel imaging biomarkers of IPF severity and disease extent.Öğe Evaluation of Change in Upper Lung Zone Radiologic Pleuroparenchymal Fibroelastosis (PPFE) as a Predictor of Mortality in Idiopathic Pulmonary Fibrosis (IPF)(Amer Thoracic Soc, 2022) Chapman, R.; Gudmundsson, E.; Zhao, A.; Mogulkoc, N.; Stewart, I.; Jones, M. G.; van Moorsel, C. H. M.[No Abstract Available]Öğe The Global Idiopathic Pulmonary Fibrosis (ipf) Collaborative Network: A Platform For Ipf Genetics(Amer Thoracic Soc, 2017) Walker, T. D.; de Andrade, J. A.; Bendstrup, E.; Blackwell, T. S.; Borie, R.; Brown, K. K.; Christie, J. D.; Collard, H. R.; Corte, T. J.; Crestani, B.; du Bois, R. M.; Eickelberg, O.; Gibson, K. F.; Henry, M.; Gudmundsson, G.; Hirani, N.; Inoue, Y.; Jenkins, R. G.; Kass, D.; Kawut, S. M.; Keane, J. M.; Kim, D.; Laurent, G.; Lederer, D. J.; Loyd, J. E.; Mogulkoc, N.; Molina-Molina, M.; Nathan, S.; Noth, I.; Ohta, K.; Parfrey, H.; Prele, C. M.; Selman, M.; Song, J.; Sterclova, M.; Tobin, M. D.; Vasakova, M.; Wolters, P. J.; Powers, J.; Waltz, A.; Schwarz, M. I.; Schwartz, D. A.Öğe The Impact of Switching to a Second Antifibrotic Therapy on Outcomes in Patients With IPF in the Empire Registry Treated With Pirfenidone or Nintedanib(Amer Thoracic Soc, 2023) Vasakova, M. K.; Mogulkoc, N.; Kramer, M.; Doubkova, M.; Plackova, M.; Mueller, V.; Studnicka, M. J.[No abstract available]Öğe Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Study in Europe(Amer Thoracic Soc, 2022) Karampitsakos, T.; Spagnolo, P.; Mogulkoc, N.; Wuyts, W. A.; Tomassetti, S.; Bendstrup, E.; Molina, M. Molina[No Abstract Available]Öğe Quantifying morphological airway damage in idiopathic pulmonary fibrosis(European Respiratory Soc Journals Ltd, 2022) Pakzad, A.; Cheung, W. K.; Quan, K.; Mogulkoc, N.; Van Moorsel, C. H.; Bartholmai, B. J.; Van Es, H. W.[No abstract available]Öğe Standardised Translation Of The King's Sarcoidosis Questionnaire (ksq) Into Eleven Languages(Amer Thoracic Soc, 2017) Birring, S.; Fletcher, H.; Tully, T.; Patel, A.; Kullberg, S.; Mogulkoc, N.; Dubaniewicz, A.; Cotta Ramusino, G.; Niimi, A.; Guan, W.; Valeyre, D.; Castillo, D.; Pereira, C. A.; Acquadro, C.; Baughman, R. P.
